Background. The evidence supporting the use of trastuzumab (T) in a metastatic setting comes from studies that included (almost) only patients who never received prior T. We investigated the effectiveness of T as first-line therapy for metastatic breast cancer (mBC) in women previously treated with T in the adjuvant setting.Materials and Methods. By using record linkage of five administrative health care databases of Lombardy, Italy, we identified 2,046women treated with T for early breast cancer (eBC) in 2006-l2009, 96 of whom developed a metastasis and were retreated with T in first-line treatment for mBC (treatment group).We compared the overall survival (OS) of these women with that of 197 women treated with T in firstline treatment for mBC, who were treated with therapies other than T for early disease (control group).We computed Kaplan-Meier 2-year OS and used a proportional hazard model to estimate the multivariate hazard ratio (HR) of death in the intervention group compared with the control group, adjusted by age, use of endocrine therapy, and site of metastasis.Results. Two-year OS was 60.0% in the treatment group and 59.5% in the control group. The adjusted HR of death in the treatment group compared with the control group was 0.79 (95% confidence interval, 0.50–1.26).Conclusion. Our data provide convincing evidence that the outcome of women receiving first-line T treatment for mBC after T failure in the adjuvant setting is comparable to that of women not receiving T for eBC. These data are of specific interest, given the unavailability of data from randomized clinical trials.

Negri, E., Zambelli, A., Franchi, M., Rossi, M., Bonifazi, M., Corrao, G., et al. (2014). Effectiveness of trastuzumab in first-line her2+ metastatic breast cancer after failure in adjuvant setting: A controlled cohort study. THE ONCOLOGIST, 19(12), 1209-1215 [10.1634/theoncologist.2014-0227].

Effectiveness of trastuzumab in first-line her2+ metastatic breast cancer after failure in adjuvant setting: A controlled cohort study

FRANCHI, MATTEO;CORRAO, GIOVANNI;
2014

Abstract

Background. The evidence supporting the use of trastuzumab (T) in a metastatic setting comes from studies that included (almost) only patients who never received prior T. We investigated the effectiveness of T as first-line therapy for metastatic breast cancer (mBC) in women previously treated with T in the adjuvant setting.Materials and Methods. By using record linkage of five administrative health care databases of Lombardy, Italy, we identified 2,046women treated with T for early breast cancer (eBC) in 2006-l2009, 96 of whom developed a metastasis and were retreated with T in first-line treatment for mBC (treatment group).We compared the overall survival (OS) of these women with that of 197 women treated with T in firstline treatment for mBC, who were treated with therapies other than T for early disease (control group).We computed Kaplan-Meier 2-year OS and used a proportional hazard model to estimate the multivariate hazard ratio (HR) of death in the intervention group compared with the control group, adjusted by age, use of endocrine therapy, and site of metastasis.Results. Two-year OS was 60.0% in the treatment group and 59.5% in the control group. The adjusted HR of death in the treatment group compared with the control group was 0.79 (95% confidence interval, 0.50–1.26).Conclusion. Our data provide convincing evidence that the outcome of women receiving first-line T treatment for mBC after T failure in the adjuvant setting is comparable to that of women not receiving T for eBC. These data are of specific interest, given the unavailability of data from randomized clinical trials.
Articolo in rivista - Articolo scientifico
Metastatic breast cancer; Overall survival; Record linkage; Trastuzumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Humans; Italy; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab; Treatment Outcome; Cancer Research; Oncology; Medicine (all)
English
1209
1215
7
Negri, E., Zambelli, A., Franchi, M., Rossi, M., Bonifazi, M., Corrao, G., et al. (2014). Effectiveness of trastuzumab in first-line her2+ metastatic breast cancer after failure in adjuvant setting: A controlled cohort study. THE ONCOLOGIST, 19(12), 1209-1215 [10.1634/theoncologist.2014-0227].
Negri, E; Zambelli, A; Franchi, M; Rossi, M; Bonifazi, M; Corrao, G; Moja, L; Zocchetti, C; La Vecchia, C
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/140455
Citazioni
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
Social impact